Ascendiant Capital Starts ARCA biopharma, Inc. (ABIO) at Buy

Ascendiant Capital initiates coverage on ARCA biopharma, Inc. (NASDAQ: ABIO) with a Buy rating and a price target of $2.00.

Analyst Ed Woo believes the selloff following the Phase 2B results has generated an attractive risk/reward.

For an analyst ratings summary and ratings history on ARCA biopharma, Inc. click here. For more ratings news on ARCA biopharma, Inc. click here.

Shares of ARCA biopharma, Inc. closed at $0.45 yesterday.

You May Also Be Interested In

• BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
• Powell Industries (POWL) PT Lowered to $235 at Cantor Fitzgerald
• Freedom Broker Upgrades Lifeway Foods (LWAY) to Buy